Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

ent of its clinical trials; that CTI cannot predict or guarantee the outcome of preclinical and clinical studies; that CTI may not obtain reimbursement for PIXUVRI in certain markets in the E.U. as planned or at all; that the conditional marketing authorization for PIXUVRI may not be renewed or may be subject to additional conditions; that the second Phase 3 clinical trial of pacritinib will not occur as planned or at all; that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities; that CTI may experience delays in the commencement of preclinical and clinical studies; risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI's other product candidates; and other risks, including, without limitation, competitive factors, technological developments, costs of developing, producing and selling PIXUVRI, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation, as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

Contacts:Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In EuropeCTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, today announced its attendance at the ... be held in Chicago, Illinois June 19th-23rd. ... #735 on June 20th-22nd. Individuals attending the meeting are ...
... SAN DIEGO, June 10, 2011 Gen-Probe Incorporated (NASDAQ: ... at the William Blair & Company 31st Annual Growth Stock ... p.m. Central Time (5 p.m. Eastern Time).  The presentation is ... a link on the investors section of Gen-Probe,s website at ...
Cached Medicine Technology:DATATRAK Exhibiting at 47th Annual DIA Meeting 2Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference 2
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/24/2014)... 2014 (HealthDay News) -- If you are a high-risk ... are not treated by a cardiologist, new research suggests. ... cardiologists left town for annual professional meetings, Harvard researchers ... who were admitted to a teaching hospital during one ... percent died when these meetings were not taking place. ...
(Date:12/22/2014)... As early as thirty, gravity begins to ... form of “jowls." The dreaded droopiness usually appears around ... line or smile lines. Aging can be fought with ... the deep facial tissues descend, jowls inevitably appear. , ... can be used under the skin to fill natural ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... York, New York (PRWEB) December 22, 2014 ... are a staple of the season. Many may be thinking ... in a span of a few weeks. Health Republic Insurance ... help of Registered Dietitian, Andrea Chernus, to provide some smart ... eat and stay healthy. , 1)    Avoid arriving at a holiday ...
Breaking Medicine News(10 mins):Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2
... of metabolic protein architecture and their advance offers ... ,,Researchers at the University of Illinois ... online edition of the Proceedings of the National Academy ... techniques of phylogenetic analysis developed in the past decade ...
... that it has a mix of properties that would ... matrix with metallic clusters that can absorb light, ... and then destroy those targeted cells with a laser. ... nanocomposite (DNC) matrix containing silver clusters that can be ...
... recently identified genetic marker for prostate cancer is linked ... ,These findings ultimately will aid the development ... susceptible to this aggressive cancer, Northwestern researchers said. Knowing ... doctors in how they treat the cancer. ...
... at Nokia have developed software that transforms a cellphone into ... lightning strike. ,A lightning bolt is an ... frequencies between 10 hertz and five gigahertz. However, the distribution ... is. ,According to the scientists, the multiple receivers ...
... toxic substance, made by certain types of bacteria found in house ... condition eczema or wheezing in children if they are exposed to ... Endotoxin is an element of the cell wall of gram-negative bacteria, ... when the bacteria dies or is damaged. ,The new ...
... The Most Powerful Weight-Loss Formula on Earth!" ... common in many parts of the world and thousands of ... is that there are few regulations to govern this booming ... ones that exist. ,Weight loss is a desperate ...
Cached Medicine News:Health News:Protein Folds Research Offers Insight into Metabolic Evolution 2Health News:Protein Folds Research Offers Insight into Metabolic Evolution 3Health News:Nanocomposite Labeled Cancer Cells Targeted and Destroyed by Using Lasers 2Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... in determining functionality of a patient's ... courses of treatment for patients receiving ... and autoimmune dieseases. Kit 030 ... diseases giving rise to high titers ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Medicine Products: